With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed
Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition of the respiratory disease specialist . The potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent. Sanofi Explores Potential Insmed Takeover Bloomberg reported Thursday…
Sanofi is actively scouting a potential acquisition of Insmed Inc. (NASDAQ:INSM), a respiratory disease specialist, as it seeks new growth avenues to mitigate its dependency on the blockbuster drug Dupixent. Insmed's pipeline includes two commercial respiratory drugs: Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension).
The former treats non-cystic fibrosis bronchiectasis, while the latter targets refractory Mycobacterium avium complex (MAC) lung disease. In Q3, Brinsupri generated $400.1 million in sales, while Arikayce sales reached $124.4 million. Insmed is projected to achieve Brinsupri revenue of $1.35 billion to $1.4 billion in 2026, and Arikayce sales of $460 million to $470 million.
The French pharmaceutical giant is also evaluating Inmed's treprostinil palmitil inhalation powder (TPIP) for four lung disease indications, as well as INS1148, INS1033, and next-generation DPP1 inhibitors in its early-stage pipeline.
Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.